How PD-1 and PD-L1 Monoclonal Antibodies Are Reshaping the Future...

Ajouter une nouvelle offre d'emploi Health

2026-06-17 07:52:22 -

How PD-1 and PD-L1 Monoclonal Antibodies Are Reshaping the Future of Cancer Immunotherapy

Cancer immunotherapy has undergone one of the most dramatic transformations in modern medicine — and at the center of this transformation are checkpoint inhibitors targeting the PD-1/PD-L1 axis. The PD-1 and PD-L1 Monoclonal Antibody Market — valued at USD 35.1 billion in 2025 and projected to reach USD 65 billion by 2035 at a CAGR of 6.3% — represents one of the largest and...

0 Commentaires 0 Parts 32 Vue 0 Aperçu